Many health and wellness stocks have faced challenges in recent years as GLP-1 weight-loss drugs like Ozempic and Wegovy upend the traditional diet market. Companies that once dominated the space have ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

WW International stock currently trades at $7 per share, over 80% below its pre-inflation shock high of $41, seen in December 2021, and has the potential for some gains. WW saw its stock trading ...

WeightWatchers’ stock was surging after the company emerged from bankruptcy two months after it was announced.

WW International stock currently trades at $7.30 per share, 82% below its pre-inflation shock high of $41, seen in December 2021, and has the potential for meaningful gains. WW saw its stock ...

WW International is shifting from a traditional weight management company to a comprehensive wellness platform. The company recently reported revenue of $206.55 million, ...

WW International, Inc. WW stock has shown a remarkable performance in the past three months, outpacing the S&P 500 and the industry.In the same time frame, WW has surged 66.8% compared with the ...

One stock that has been struggling out of the gate in 2024 is WW International (NASDAQ: WW), better known as WeightWatchers. Already down more than 50% this year, it has been in a rapid free fall ...

What happened. According to data compiled by S&P Global Market Intelligence, veteran dieting services company WW International's (WW-5.03%) stock was up by more than 7% week to date as of late ...

Shares of WW International ()-- parent company of Weight Watchers -- continued to slip this week.The stock is down 19.3% as of this writing. Even with shares still up over 100% year-to-date (YTD ...

To tackle its $1.5B debt burden and dwindling revenue, WW International (NASDAQ:WW), known more commonly as Weight Watchers, is reportedly in talks with its creditors to swap some of its debt for ...

WW International fell after cutting its revenue guidance for the year, citing supply constraints for a drug used for weight loss and a shift in its subscriber base.. The company, which sells ...